A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $18
Black Diamond Theraptcs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Black Diamond Therapeutic Analyst Ratings
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Raises Price Target to $15
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Black Diamond Theraptcs Price Target Maintained With a $16.00/Share by Wedbush
Black Diamond Therapeutic Analyst Ratings
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Black Diamond Theraptcs Price Target Maintained With a $16.00/Share by Wedbush
Black Diamond Therapeutic Analyst Ratings
Wedbush Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)